Ken Griffin Aptinyx Inc. Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.23 - $0.34 $5,973 - $8,830	25,973 New	25,973 $7,000
Q1 2022 May 16, 2022	BUY	$2.27 - $3.62 $20,582 - $32,822	9,067 Added 37.98%	32,940 $75,000
Q4 2021 Feb 14, 2022	SELL	$2.11 - $3.0 $17,166 - $24,408	-8,136 Reduced 25.42%	23,873 $63,000
Q3 2021 Nov 15, 2021	SELL	$2.21 - $2.89 $11,785 - $15,412	-5,333 Reduced 14.28%	32,009 $75,000
Q2 2021 Aug 16, 2021	SELL	$2.39 - $3.5 $151,272 - $221,529	-63,294 Reduced 62.89%	37,342 $105,000
Q4 2020 Feb 16, 2021	BUY	$2.93 - $4.3 $294,863 - $432,734	100,636 New	100,636 $348,000
Q3 2020 Nov 16, 2020	SELL	$3.05 - $4.99 $84,000 - $137,429	-27,541 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.99 - $4.4 $54,806 - $121,180	27,541 New	27,541 $115,000
Q4 2019 Feb 14, 2020	SELL	$2.84 - $4.25 $208,328 - $311,758	-73,355 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.08 $81,975 - $111,486	-27,325 Reduced 27.14%	73,355 $256,000
Q2 2019 Aug 14, 2019	BUY	$2.95 - $4.38 $141,818 - $210,564	48,074 Added 91.39%	100,680 $336,000
Q1 2019 May 15, 2019	SELL	$3.99 - $19.33 $710,132 - $3.44 Million	-177,978 Reduced 77.19%	52,606 $0
Q4 2018 Feb 14, 2019	SELL	$16.15 - $28.93 $1.35 Million - $2.41 Million	-83,421 Reduced 26.57%	230,584 $3.81 Million
Q3 2018 Nov 13, 2018	BUY	$20.21 - $31.85 $4.43 Million - $6.98 Million	219,168 Added 231.1%	314,005 $0
Q2 2018 Aug 10, 2018	BUY	$19.83 - $24.17 $1.88 Million - $2.29 Million	94,837 New	94,837 $0

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.